一分钟看懂
这是一项关于淋巴瘤的I 期 / II 期研究，登记的药物或干预包括MK-1045，当前状态为招募中。登记地点显示中国北京、广州、上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
MK-1045 · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer hospital ( Site 1701) · 北京
- Sun Yat-Sen University Cancer Center ( Site 1712) · 广州
- Fudan University Shanghai Cancer Center ( Site 1711) · 上海
公开的入选条件
- The main inclusion criteria include but are not limited to the following:
- * Has disease that has relapsed (disease progression after remission) or is refractory (failure to achieve complete or partial response) to at least 2 prior systemic lines of therapy.
- * Has a histologically confirmed diagnosis of follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL).
- * DLBCL participants only: has progressed after or is ineligible for transplant and chimeric antigen receptor T (cell) (CAR-T) therapy.
- * Has provided tumor tissue sample (archival or newly obtained, if performed per standard of care).
- * Has documented retained expression of cluster of differentiation 19 (CD19) in tumor tissue obtained by biopsy after disease progression on CD19-targeting therapy, if experienced disease progression after prior CD19-targeting therapy.
- * Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy if has a history of HIV infection.
- * Has undetectable hepatitis B virus (HBV) viral load and received and will continue to receive HBV antiviral therapy if hepatitis B surface antigen (HBsAg)-positive.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07519772；登记信息更新于 2026-09-17。